Lupin receives approval from U.S. FDA for Chlorpromazine Hydrochloride Tablets USP

Global pharma major Lupin Limited (Lupin) today announced that its wholly-owned subsidiary, Lupin Inc., based in Somerset, New Jersey, has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, to market a generic equivalent to the reference listed drug (RLD), Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg of Upsher-Smith Laboratories, LLC. This product will be manufactured at Lupin's Somerset facility in the U.S.

Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S. (IQVIA MAT Mar 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 930.65 as compared to the previous close of Rs. 930.50. The total number of shares traded during the day was 13540 in over 776 trades.

The stock hit an intraday high of Rs. 934.15 and intraday low of 925.85. The net turnover during the day was Rs. 12594722.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Subsidiary USFDA ANDA Approval ChlorpromazineHydrochloride Tablets